Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.

J Gastroenterol · 2025 · PMC11880175 · PMID 39614927

Europe PMC DOI

hedged sentences

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

borderline significantp = 0.067so close (0.05 < p ≤ 0.1)

In the IPTW-adjusted Cox proportional hazards model for the complete-case dataset, nal-IRI + 5-FU/LV was associated with a borderline significant OS benefit (HR 0.812; 95% CI 0.651–10.14; p = 0.067).

also in 11,409 other papers

a favorable trendno p-value reported

On the other hand, nal-IRI + 5-FU/LV showed a favorable trend in HR for OS compared with S-1 in the complete-case analysis dataset, but a statistical significance showed marginal in contrast to multiple imputed dataset.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.